Skip to Main Content

3,294

Views

1

CrossRef citations to date

0

Altmetric

Original Research

Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis

Andreas Nikolaoua Modelling and Simulation, Evidera, London, UKCorrespondence[email protected]
View further author information

,

Apoorva Ambavaneb Modelling and Simulation, Evidera, Waltham, MA, USAView further author information

,

Anshul Shahb Modelling and Simulation, Evidera, Waltham, MA, USAView further author information

,

Wenkang Mab Modelling and Simulation, Evidera, Waltham, MA, USAView further author information

,

Jon Tosha Modelling and Simulation, Evidera, London, UKView further author information

,

Venediktos Kapetanakisa Modelling and Simulation, Evidera, London, UKView further author information

,

Jenny Willsonc GlaxoSmithKline, Upper Providence, PA, USAView further author information

,

Feng Wangc GlaxoSmithKline, Upper Providence, PA, USAView further author information

,

Cosmina Hogead GlaxoSmithKline, Philadelphia, PA, USA

https://orcid.org/0000-0002-0686-2395 View further author information

,

Boris Gorshd GlaxoSmithKline, Philadelphia, PA, USAView further author information

,

Ben Gutierrezd GlaxoSmithKline, Philadelphia, PA, USAView further author information

,

Sandhya Saprad GlaxoSmithKline, Philadelphia, PA, USAView further author information

,

Attaya Suvannasankhae Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, USAView further author information

&

Yevgeniy Samyshkinf GlaxoSmithKline, Brentford, Middlesex, UK

https://orcid.org/0000-0003-3561-5585 View further author information